Boston Molecules is a leading custom antibody developer facilitated with cutting edge technologies and innovations. Our B-cell cloning antibody platform is emerging as the world’s best monoclonal antibody development strategies that outperformed traditional hybridoma technologies by more than 10 fold increase of positive colony numbers and superior affinities in selected antibodies. Cohesive with our Bioinformatics scientists and Crystallography scientists, our custom antibody services deliver >95% successful projects by guaranteed antibody development strategies including antigen 3D structure prediction and homologous sequence exclusions.